Core Viewpoint - The release of the "Clinical Practice Guidelines for Ion Radiation Therapy (2025 Edition)" and the "Quality Assurance Guidelines for Proton Radiation Therapy Systems (2025 Edition)" marks the establishment of systematic and comprehensive industry standards for high-end radiation therapy in China [1][2]. Group 1: Industry Standards and Contributions - The guidelines were developed by a team including experts from Guangzhou Taihe Hospital, part of Meizhong Jiahe Medical Technology Development Group, along with top public institutions [1]. - Meizhong Jiahe has been involved in the formulation of national guidelines four times in recent years, contributing to six national standard outcomes, indicating a shift from occasional participation to a sustained and systematic role in standard-setting [1][2]. - Industry experts view participation in national standard formulation as a certification of technical and quality systems, reflecting long-term accumulation of capabilities [1]. Group 2: Competitive Position and Growth Potential - With stricter regulations and detailed standards, the industry is entering a phase where stronger capabilities lead to faster expansion, benefiting Meizhong Jiahe in approvals, collaborations, academic branding, and clinical appeal [2]. - All four proton therapy rooms at Guangzhou Taihe Hospital are now operational, leading to rapid growth in treatment volume and solidifying its position as a particle center in South China [2]. - Meizhong Jiahe's long-term performance, marked by its four entries into national guidelines and six contributions, positions it among the few social medical entities in the top tier of the industry, enhancing its competitive advantage in high-end radiation therapy [2].

Core Viewpoint - The company emphasizes its focus on health care services and modern medical technology application, highlighting its commitment to investor returns and ongoing development despite current operating losses [1] Group 1: Company Overview - The company operates two major comprehensive medical campuses: Xi'an High-tech Hospital and Xi'an International Medical Center Hospital, with a service capacity of ten thousand beds [1] - The company is equipped with internationally advanced hardware, including the upcoming proton therapy center, the first of its kind in Northwest China [1] - The medical team consists of highly qualified professionals, including "National Famous Doctors," professors from top-tier institutions, and experts receiving government special allowances [1] Group 2: Financial Performance and Investor Returns - Since its transformation in 2019 to focus on medical services, the company is in a growth phase, with new medical projects gradually coming online [1] - Although the company has been narrowing its net profit losses, it has not yet achieved profitability, and its revenue scale has not yet covered operational costs and expenses [1] - The company has consistently aimed to provide stable and sustainable dividends to shareholders when conditions allow [1]

Core Insights - The National Healthcare Security Administration (NHSA) is accelerating the clinical application of over 100 new treatment projects, including artificial hearts, cochlear implants, and proton radiation therapy [1] Group 1 - The NHSA has released 28 batches of medical service pricing guidelines to facilitate the rapid entry of new products and technologies into clinical use [1] - More than 100 new pricing items related to new products have been added [1]